PeopleBio피플바이오

PeopleBio's shares have fallen sharply over the past year, and the company remains deeply loss-making with heavy borrowings.

PeopleBio sells AlzOn, a blood-based Alzheimer's diagnostic test, in Korea and through export partners, and holds CE marking for Europe. Revenue has shrunk for two straight years, and the company reported large operating and net losses in 2025 and the first half of 2026. Its share price is down about 61% over one year and trades near ₩561, with the company's borrowings far larger than its cash.

What stands out

• Trailing revenue is about ₩3.7B against an operating loss of about ₩6.0T, an operating margin of roughly -166%.
• Borrowings are about ₩76B versus cash of about ₩0.3B, and liabilities are about 283% of equity.
• Annual revenue fell 23.6% in 2025 after falling 16.2% in 2024, and trailing free cash flow is about -₩9.9B.
• Shares trade at about 0.5 times book value, and the company pays no dividend; the data has no P/E because earnings are negative.
• Recent filings are mostly share consolidation decisions, third-party collateral provisions and a short-term borrowing increase; the data contains no news headlines to explain them.

What to watch

• Upcoming filings on the share consolidation, which the company has amended several times.
• Whether the company can refinance or repay its borrowings and fund its cash burn.
• Any further third-party collateral provisions or new borrowings disclosed in filings.